Drug intelligence / Profile preview

TB682

Development stage: Discontinued
Lead developer: Twinpig Biolab
Modality: Small Molecules

Overview

TB682 is a small molecule therapeutic candidate that was under development by T-Bird Pharmaceuticals. While specific details regarding its mechanism of action and target are not widely documented in public clinical databases, it was primarily investigated for its potential in treating various forms of cancer. The development of TB682 appears to have been discontinued or stalled, as there are no recent records of active clinical trials or regulatory filings associated with this specific code name.

Beyond the preview

Go deeper on TB682.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB682.

Explore the full profile